| Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives IM Bouligny, KR Maher, S Grant Blood reviews 57, 100996, 2023 | 16 | 2023 |
| Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation E Katsanis, K Maher, DJ Roe, RJ Simpson EJHaem 1 (1), 286-292, 2020 | 12 | 2020 |
| Post-allogeneic stem cell transplantation maintenance dasatinib in Philadelphia chromosome positive acute leukemia KR Maher, A McBride, A Amaraneni, O Okolo, SR Farooqui, F Anwer Biology of Blood and Marrow Transplantation 23 (3), S289, 2017 | 8 | 2017 |
| A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-Naïve myelofibrosis H Ali, A Kishtagari, K Maher, SR Mohan, K Ansaldo, X Wang, K Chamoun, ... Blood 140 (Supplement 1), 3986-3987, 2022 | 6 | 2022 |
| Cellular transplant therapies for globoid cell leukodystrophy: preclinical and clinical observations KR Maher, AM Yeager Journal of neuroscience research 94 (11), 1180-1188, 2016 | 6 | 2016 |
| Augmenting venetoclax activity through signal transduction in AML IM Bouligny, KR Maher, S Grant Journal of cellular signaling 4 (1), 1, 2023 | 5 | 2023 |
| Implementation of outpatient high-dose cytarabine (HiDAC) for AML: evaluation of the impact of transitioned outpatient chemotherapy in an oncology care model setting L Jafari, J Hussain, R Krishnadasan, KR Maher, F Anwer, E Elquza, ... Blood 134, 2153, 2019 | 5 | 2019 |
| Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-naïve patients with myelofibrosis: long term follow up from XPORT-MF-034 suggestive of disease modification SK Tantravahi, A Kishtagari, K Maher, S Mohan, JT Prchal, X Wang, ... Blood 142, 622, 2023 | 4 | 2023 |
| Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia IM Bouligny, G Murray, M Doyel, T Patel, J Boron, V Tran, J Gor, Y Hang, ... EJHaem 4 (2), 381-392, 2023 | 4 | 2023 |
| A case of myeloid sarcoma following allogeneic HSCT presenting as localized hip pain S Zhang, C Charlton, A Amaraneni, K Maher Case Reports in Hematology 2019, 2019 | 3 | 2019 |
| Safety, pharmacodynamic, and anti-tumor activity of sl-172154 as monotherapy and in combination with azacitidine (Aza) in relapsed/refractory (R/R) acute myeloid leukemia (Aml … N Daver, AS Stein, D Bixby, W Chai-Ho, JF Zeidner, K Maher, DA Stevens, ... Blood 142, 4278, 2023 | 2 | 2023 |
| A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve … K Maher, RK Rampal, P Bose, NA Podoltsev, CN Harrison, J Hong, ... Blood 142, 3209, 2023 | 2 | 2023 |
| The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine. M Doyel, IM Bouligny, G Murray, T Patel, J Boron, V Tran, J Gor, Y Hang, ... Journal of Clinical Oncology 41 (16_suppl), e19048-e19048, 2023 | 2 | 2023 |
| Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034. H Ali, A Kishtagari, KR Maher, S Mohan, JT Prchal, X Wang, K Chamoun, ... Journal of Clinical Oncology 41 (16_suppl), 7063-7063, 2023 | 2 | 2023 |
| Prevention and management of infections after exposure to ionising radiation KR Maher, IM Bouligny, AM Yeager Journal of Radiological Protection 41 (4), R176, 2021 | 2 | 2021 |
| Outcomes of induction with venetoclax in combination with decitabine, azacitidine, or low-dose cytarabine for treatment of AML: A real-world retrospective analysis IM Bouligny, KR Maher Blood 138, 2335, 2021 | 2 | 2021 |
| Haploidentical transplant for myelofibrosis: a single institution experience P Zhang, ME Coffield, KR Maher Biology of Blood and Marrow Transplantation 26 (3), S281-S282, 2020 | 2 | 2020 |
| Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia IM Bouligny, G Murray, M Doyel, T Patel, J Boron, V Tran, J Gor, Y Hang, ... Medical Oncology 41 (3), 1-12, 2024 | 1 | 2024 |
| First-Line Venetoclax and a Hypomethylating Agent or Conventional Chemotherapy in Older Adults with IDH-Mutated AML I Bouligny, G Murray, T Ho, J Gor, K Zacholski, N Wages, S Grant, ... Blood 142, 1488, 2023 | 1 | 2023 |
| Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022 IM Bouligny, KR Maher, S Grant Cancers 15 (13), 3292, 2023 | 1 | 2023 |
